(+886) 2-2655-7790

(+886) 2-2655-7730

Rm. ER12A, 17F.-1, No. 3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.)​

選單

New Drug

GM-XANTHO

INDICATION
Atopic Dermatitis
MECHANISM
  • Anti-inflammatory
  • To diminish the levels of pro-inflammatory cytokine RNA, pro-inflammatory immune cells, and IgE levels, concomitant with an augmentation in the levels of the anti-inflammatory cytokine IL-10 and IL-10-secreting cells.
STATUS
  • Phase II
ADVANTAGES
  • Botanical new drugs have high barriers to entry, and raw materials are difficult to obtain.
  • The effect is as good as steroids but not recur in AD
  • Safety and long-term use
MARKET

The Global Data estimates that in 2027, the sales were total $18.3B for atopic dermatitis worldwide.

  • GM-XANTHO demonstrated the capacity to diminish the levels of pro-inflammatory cytokine RNA, pro-inflammatory immune cells, and IgE levels, concomitant with an augmentation in the levels of the anti-inflammatory cytokine IL-10 and IL-10-secreting cells. Consequently, this led to a reduction in epidermal thickness, immune infiltrate, and inflammatory responses, ultimately achieving therapeutic efficacy in the treatment of atopic dermatitis.
  • GM-XANTHO has completed CMC, which has manufactured in accordance with GMP/PIS specifications. GM-XANTHO has completed pre-clinical pharmacology, pharmacokinetics and toxicity tests to confirm the efficacy of GM-XANTHO in the treatment of atopic dermatitis and has low side effects.